Anticancer agent 199

• UNSPSC Description:

  Anticancer agent 199 (Compound G-4) induces apoptosis in triple negative breast cancer (TNBC) cells via the mitochondrial pathway through inhibiting EGFR, AKT and MAPK pathways. Anticancer agent 199 also induces Ferroptosis by down-regulating LCN2. Anticancer agent 199 inhibits TNBC cell viability and migration, and induces S phase cell cycle arrest. Anticancer agent 199 is a derivate of cyclin-dependent kinase inhibitor Rocovitine[1].

• Target Antigen:

  Apoptosis; Ferroptosis

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/anticancer-agent-199.html

• Solubility:

  10 mM in DMSO

• Smiles:

  OCCN1CCC(CC1)C2CCN(CC2)C3=NC4=C(C(NCC5=CC=C(C(F)=C5)Cl)=N3)N=CN4C6CCCC6

• Molecular Weight:

  556.12

• References & Citations:

  [1]Sun G, et al. G-4 inhibits triple negative breast cancer by inducing cell apoptosis and promoting LCN2-dependent ferroptosis. Bioc

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  9007-83-4